'Bleeding risk' presentation slideshows

1.35k views • 134 slides

Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy

Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy. By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine. Introduction.

849 views • 57 slides

Antistolling in AF Het begin van een nieuw tijdperk?

Antistolling in AF Het begin van een nieuw tijdperk?. Dr RG Tieleman Martini Ziekenhuis Groningen. CVA en Atriumfibrilleren: de feiten. CVA is de belangrijkste complicatie van AF AF is geassocieerd met een 5x verhoogde kans op CVA

810 views • 55 slides

2007 ESC NSTE-ACS GUIDELINES

2007 ESC NSTE-ACS GUIDELINES. CASE 1: 52-y-o man with previous CABG and typical chest pain at rest since 12 hours. CASE 1: 52-y-o man with previous CABG and typical chest pain at rest since 12 hours CASE 2:

742 views • 54 slides

TVP ed Embolia Polmonare: Definizione

TVP ed Embolia Polmonare: Definizione. TVP Sintomi & Segni. NON SPECIFICI o ASSENTI. Dolore Tensione Edema. DD: crampi o strappi muscolari, rottura cisti poplitea, contusioni, artriti anca-ginocchio, gotta, tendiniti. . EP Sintomi & Segni. NON SPECIFICI, dipendono da:.

631 views • 39 slides

Hot Topics In Anticoagulation

Hot Topics In Anticoagulation. Deborah Zeitlin, Pharm.D. Assistant Professor of Pharmacy Practice Butler University College of Pharmacy and Health Sciences Clinical Pharmacist Specialist, Clarian Health. Disclosure Statement.

624 views • 38 slides

JM ten Berg, St Antonius Hospital

370 views • 36 slides

Venous Thromboembolism

472 views • 35 slides

THROMBOPHILIA

THROMBOPHILIA. Thrombophilia. Thrombophilia i s technical term for hypercoagulable state Thrombosis (arterial or venous) is produced by a shift in the balance between procoagulant and profibrynolytic system. Thrombophilia. inherited acquired. 3. Epidemiology of VTE.

1.05k views • 34 slides

455 views • 34 slides

447 views • 34 slides

Antiplatelet Therapy: Essential Questions

Antiplatelet Therapy: Essential Questions. Gregory C HadlocK, PharmD, PhD, BCPS. Objectives for pharmacists. Identify appropriate indications for antiplatelet (AP) therapy Evaluate bleeding risks of patients on AP therapy

327 views • 32 slides

Bridge Therapy: Peri-operative Anticoagulation Management Amjad AlMahameed, MD, MPH

Bridge Therapy: Peri-operative Anticoagulation Management Amjad AlMahameed, MD, MPH Division of Cardiology Beth Israel Deaconess Medical Center Boston. mechanical heart valves. A Fib w risk factors for emboli. recent VTE (< 3 months). hypercoaguable states. RATIONALE FOR BRIDGING.

393 views • 24 slides

Natural History Conclusions Lancet, June 18, 1960, 1309-1312

Natural History Conclusions Lancet, June 18, 1960, 1309-1312. PE untreated has high mortality (5/19 in randomized trial consistent with 23-87% in retrospective analyses) Waiting is dangerous since death happened in first two weeks. Anticoagulation greatly decreased mortality.

396 views • 23 slides

August 14th David Sutherland

August 14th David Sutherland. Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs. Anticoagulants and antiplatelet drugs are agents that reduce the ability of blood to form clots, or coagulate i.e. stop bleeding. What are they??.

224 views • 22 slides

Postoperative Anticoagulation Re-administration A Dilemma to be solved

Postoperative Anticoagulation Re-administration A Dilemma to be solved. Dr. Rania Hassan Dr. Dina ElEbiary. Case.

761 views • 19 slides

Preventing a Second Stroke

338 views • 18 slides

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015. Abstract. Background: In patients with Afib, is Heparin bridging necessary during interruption of warfarin therapy for elective invasive procedures.

186 views • 17 slides

Question: How should we manage periprocedural anticoagulation?

Question: How should we manage periprocedural anticoagulation? Paper: Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures Todd H. Baron, M.D., Patrick S. Kamath , M.D., and Robert D. McBane , M.D.

196 views • 11 slides

Observation of early strut coverage after polymer-free biolimus-a9 coated stent by optical frequency domain imaging

An 80-year-old male patient with an acute myocardial infarction in the mid left anterior descending artery was treated with a BioFreedom stent (2.5 u00d7 24 mm). A month later, the patient was re-admitted with chest pain. A significant coronary artery stenosis in the mid left anterior descending artery more progressive than the previous one (not involving proximal stent-edge) was treated with percutaneous coronary intervention. Then, optical frequency domain imaging of the Biofreedom stent revealed a fully expanded stent with complete stent apposition in its entire length and strut coverage with neointimal hyperplasia.

26 views • 2 slides